BG105097A - Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disorders - Google Patents

Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disorders

Info

Publication number
BG105097A
BG105097A BG105097A BG10509700A BG105097A BG 105097 A BG105097 A BG 105097A BG 105097 A BG105097 A BG 105097A BG 10509700 A BG10509700 A BG 10509700A BG 105097 A BG105097 A BG 105097A
Authority
BG
Bulgaria
Prior art keywords
apnea
disorders
norcisapride
bulimia
treatment
Prior art date
Application number
BG105097A
Other languages
Bulgarian (bg)
English (en)
Inventor
Paul Rubin
Timothy Barberich
Original Assignee
Sepracor, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor, Inc filed Critical Sepracor, Inc
Publication of BG105097A publication Critical patent/BG105097A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG105097A 1998-06-15 2000-12-27 Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disorders BG105097A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8922598P 1998-06-15 1998-06-15
US12223699P 1999-03-01 1999-03-01
PCT/US1999/013100 WO1999065490A2 (en) 1998-06-15 1999-06-10 Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders

Publications (1)

Publication Number Publication Date
BG105097A true BG105097A (en) 2002-02-28

Family

ID=26780367

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105097A BG105097A (en) 1998-06-15 2000-12-27 Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disorders

Country Status (24)

Country Link
US (2) US6559165B1 (xx)
EP (1) EP1087765B1 (xx)
JP (1) JP2003522103A (xx)
KR (3) KR20060020739A (xx)
CN (1) CN1312716A (xx)
AR (1) AR020327A1 (xx)
AT (1) ATE291916T1 (xx)
AU (1) AU764474B2 (xx)
BG (1) BG105097A (xx)
BR (1) BR9911302A (xx)
CA (1) CA2334369A1 (xx)
CZ (1) CZ20004736A3 (xx)
DE (1) DE69924488T2 (xx)
ES (1) ES2237117T3 (xx)
HK (1) HK1040059A1 (xx)
HU (1) HUP0102026A3 (xx)
IL (1) IL140117A0 (xx)
IS (1) IS5755A (xx)
NO (1) NO20006358L (xx)
NZ (3) NZ535055A (xx)
PL (1) PL345325A1 (xx)
SK (1) SK19062000A3 (xx)
TR (6) TR200003707T2 (xx)
WO (1) WO1999065490A2 (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US7846180B2 (en) 1999-06-22 2010-12-07 Ethicon Endo-Surgery, Inc. Tissue fixation devices and methods of fixing tissue
US8287554B2 (en) 1999-06-22 2012-10-16 Ethicon Endo-Surgery, Inc. Method and devices for tissue reconfiguration
US6663639B1 (en) 1999-06-22 2003-12-16 Ndo Surgical, Inc. Methods and devices for tissue reconfiguration
US6835200B2 (en) 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
US6821285B2 (en) 1999-06-22 2004-11-23 Ndo Surgical, Inc. Tissue reconfiguration
KR20070087678A (ko) 2004-12-20 2007-08-28 컬리지움 파마슈티칼, 인코포레이티드 수면 장애용 약제 조성물
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
US8852216B2 (en) 2007-03-23 2014-10-07 Ethicon Endo-Surgery, Inc. Tissue approximation methods

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR748807A (fr) 1932-03-10 1933-07-10 Gulf Refining Co Perfectionnements à la fabrication d'hydrocarbures
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5137896A (en) 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4598123A (en) 1983-07-14 1986-07-01 Unites States Steel Corporation Impact modified methyl methacrylate polymer
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4800162A (en) 1987-04-01 1989-01-24 Sepracor, Inc. Method for resolution of steroisomers in multiphase and extractive membrane reactors
US5057427A (en) 1988-04-07 1991-10-15 Sepracor, Inc. Method for resolution of stereoisomers
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8823980D0 (en) * 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
US5116407A (en) 1988-10-13 1992-05-26 Courtaulds Coatings Limited Antifouling coatings
JPH02188523A (ja) 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5075290A (en) 1989-06-28 1991-12-24 University Of Virginia Alumni Patents Foundation Use of adenosine, adenosine analogs or nucleoside uptake blockers, e.g. dipyridamole, as drug treatments for obstructive sleep apnea and snoring
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5356934A (en) 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
CA2126354C (en) * 1991-12-21 2006-07-11 Gareth John Sanger Use of 5-ht4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
JPH08502031A (ja) 1992-07-07 1996-03-05 セプラコア インコーポレーテッド 胃食道逆流疾患およびその他の障害を治療するために▲（＋）▼シサプリドを使用する方法
WO1994001112A1 (en) 1992-07-07 1994-01-20 Sepracor Inc. Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
CA2166730A1 (en) 1993-07-06 1995-01-19 Robert T. Sims H2 antagonist-gastrointestinal motility agent combinations
US5407953A (en) 1994-02-04 1995-04-18 Morgan; Julia A. Treating apnea/hypopnea/snoring in humans
US5502067A (en) 1994-02-04 1996-03-26 Morgan; Julia A. Treating apneahypopnea/snoring in humans
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735475B1 (fr) * 1995-06-13 1997-07-11 Synthelabo Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
HUP0003078A3 (en) * 1997-07-11 2002-02-28 Janssen Pharmaceutica Nv (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders
DE69924375T2 (de) 1998-06-15 2005-08-11 Sepracor Inc. Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms

Also Published As

Publication number Publication date
TR200103757T2 (tr) 2002-06-21
ATE291916T1 (de) 2005-04-15
TR200003707T2 (tr) 2001-06-21
AU764474B2 (en) 2003-08-21
DE69924488D1 (de) 2005-05-04
AR020327A1 (es) 2002-05-08
US7064138B2 (en) 2006-06-20
JP2003522103A (ja) 2003-07-22
NO20006358D0 (no) 2000-12-13
SK19062000A3 (sk) 2001-07-10
TR200103760T2 (tr) 2002-06-21
BR9911302A (pt) 2001-03-13
CN1312716A (zh) 2001-09-12
TR200103758T2 (tr) 2002-06-21
CA2334369A1 (en) 1999-12-23
NZ526108A (en) 2004-10-29
NO20006358L (no) 2001-02-13
TR200103762T2 (tr) 2002-05-21
IS5755A (is) 2000-12-08
NZ508825A (en) 2003-09-26
HUP0102026A3 (en) 2002-12-28
EP1087765A2 (en) 2001-04-04
HUP0102026A2 (hu) 2001-11-28
PL345325A1 (en) 2001-12-17
EP1087765B1 (en) 2005-03-30
AU4678499A (en) 2000-01-05
KR20060067985A (ko) 2006-06-20
CZ20004736A3 (cs) 2001-09-12
KR20060020739A (ko) 2006-03-06
KR20010052740A (ko) 2001-06-25
WO1999065490A2 (en) 1999-12-23
NZ535055A (en) 2006-04-28
DE69924488T2 (de) 2005-09-08
US6559165B1 (en) 2003-05-06
IL140117A0 (en) 2002-02-10
WO1999065490A3 (en) 2000-04-13
US20030158229A1 (en) 2003-08-21
HK1040059A1 (zh) 2002-05-24
TR200103759T2 (tr) 2002-06-21
ES2237117T3 (es) 2005-07-16

Similar Documents

Publication Publication Date Title
BG105096A (en) Use of optically pure(+)norcisapride for treaing apnea, bulimia and other disorders
IL256054A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
WO2003018516A3 (en) Glucagon-like peptide-1 analogs
PL323825A1 (en) Peptidyloheterocycli compounds useful in treating diorders associated with thrombosin
AU3111695A (en) Substituted pyrimidine compounds and the use thereof
AU3111595A (en) The use of thiazole and thiadiazole compounds
AU3111395A (en) Triazole compounds and the use thereof
DE60322417D1 (en) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1,8-naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
BG105097A (en) Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disorders
WO2000051582A3 (en) Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
AU2634597A (en) Compounds with growth hormone releasing properties
IL115589A0 (en) Use of cck-b antagonists in pharmaceutical compositions
WO2000010554A3 (en) Methods and compositions employing optically pure s(+) vigabatrin
NO990450L (no) Behandling av sinnslidelser
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
EP1464333A3 (en) Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
EP1468685A3 (en) Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
FR2802101B1 (fr) Association de cymemazine et d'un neuroleptique atypique
GB2368524B (en) Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders
IL129267A (en) Pharmaceutical compositions comprising histamine and/or serotonin for treatment of urinary incontinence
ZA200007259B (en) Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders.
HUP0202145A3 (en) The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders
ZA200007258B (en) Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders.